Related Experiment Videos
Immune cell lncRNAs reprogram the tumor microenvironment
Chaitali Bhadiadra1, Chunru Lin1, Liuqing Yang2
1Department of Molecular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Science, Houston, TX 77030, USA.
Trends in Cell Biology
|July 17, 2026
Summary
Long noncoding RNAs (lncRNAs) within immune cells control their function in the tumor microenvironment (TME). Understanding these immune-intrinsic lncRNAs offers new avenues for cancer immunotherapy.
Area of Science:
- Immunology
- Molecular Biology
- Cancer Research
Background:
- Long noncoding RNAs (lncRNAs) are recognized regulators of the tumor microenvironment (TME).
- Their specific roles within immune cells of the TME are often overlooked.
- This review focuses on the cell-intrinsic functions of lncRNAs in immune populations.
Purpose of the Study:
- To systematically review the cell-intrinsic roles of lncRNAs in key immune cell types within the TME.
- To highlight lncRNAs acting as molecular switches in immune cell states.
- To explore the potential of lncRNAs as biomarkers and therapeutic targets in immuno-oncology.
Main Methods:
- Systematic literature review of immune cell-intrinsic lncRNAs.
- Analysis of lncRNA regulation in CD8+ T cell exhaustion, CD4+ T cell polarization, NK cell cytotoxicity, dendritic cell antigen presentation, and macrophage programming.
- Examination of exosomal lncRNA functions.
Main Results:
- Immune cell-intrinsic lncRNAs critically govern T cell exhaustion and polarization, NK cell function, antigen presentation, and macrophage inflammatory responses.
- Certain lncRNAs act as molecular switches, modulating immune cells between antitumor and immunosuppressive states.
- Exosomal lncRNAs mediate intercellular communication within the TME.
Conclusions:
- Immune cell-intrinsic lncRNAs are crucial regulators of immune cell function within the TME.
- Targeting these lncRNAs presents opportunities for novel cancer biomarkers and therapies.
- Integrating lncRNA biology into precision immuno-oncology is a promising future direction.
Related Concept Videos
lncRNA - Long Non-coding RNAs
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...
The Tumor Microenvironment
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
The Tumor Microenvironment
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Stem Cells and Tumor Maintenance
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer Stem Cells and Tumor Maintenance
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...